PPARS, metabolic disease and atherosclerosis

Pharmacological Research

Volumn 44, Issue 5, 2001, Pages 345-352

  Fruchart, Jean Charles ^a   Staels, Bart ^a   Duriez, Patrick ^a  

^a UNIV LILLE   (France)

Author keywords

Atherosclerosis; Lipoprotein metabolism; Metabolic disease; PPAR alpha

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; BEZAFIBRATE; CIPROFIBRATE; CLOFIBRATE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RECEPTOR SUBTYPE; RETINOID X RECEPTOR;

ADIPOSE TISSUE; ANIMAL MODEL; ATHEROSCLEROSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DYSLIPIDEMIA; FATTY ACID METABOLISM; GENE EXPRESSION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; INFLAMMATION; INSULIN SENSITIVITY; LIPID METABOLISM; LIPOPROTEIN METABOLISM; MAJOR CLINICAL STUDY; METABOLIC DISORDER; MOUSE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; REVIEW; THROMBOSIS;

EID: 0035193079     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1006/phrs.2001.0871     Document Type: Article

References (65)

1. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
2. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
3. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the cholesterol and recurrent events trial
4. Triglycerides as a risk factor for coronary artery disease
5. Quantity and function of high density lipoprotein as an indicator of coronary atherosclerosis
6. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
7. Differential expression of peroxisome proliferator-activated receptors (PPARs): Tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat
8. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
9. The PPARs: From orphan receptors to drag discovery
10. Effects of clofibrate, bezafibrate, fenofibrate and probucol on plasma lipolytic enzymes in normolipaemic subjects
11. Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates
12. Effects of fenofibrate on high and low density lipoprotein metabolism in heterozygous familial hypercholesterolemia
13. Negative regulation of the human apolipoprotein A-I promoter by fibrates can be attenuated by the interaction of the peroxisome proliferator-activated receptor with its response element
14. Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferatoractivated receptor
15. Efficacy of ciprofibrate in primary type II and IV hyperlipidemia: The Italian multicenter study
16. Low density lipoprotein density and composition in hypercholesterolaemic men treated with HMG CoA reductase inhibitors and gemfibrozil
17. Fenofibrate and LDL metabolic heterogeneity in hypercholesterolemia
18. Bezafibrate fails to directly modulate HMGCoA reductase or LDL catabolism in human mononuclear cells
19. The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation
20. Peroxisome proliferator-activated receptors gamma and alpha mediate in vivo regulation of uncoupling protein (UCP-1, UCP-2, UCP-3) gene expression
21. Influence of gemfibrozil and clofibrate on metabolism of cholesterol and plasma triglycerides in man
22. PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene
23. The effect of human C apolipoproteins on the in vitro hepatic metabolism of triglyceride emulsions in the rat
24. Regulation of the hepatic uptake of triglyceride-rich lipoproteins in the rat. Opposing effects of homologous apolipoprotein E and individual C apoproteins
25. Modulation of lipoprotein B binding to the LDL receptor by exogenous lipids and apolipoproteins CI, CII, CIII, and E
26. Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles
27. Further characterization of the metabolic properties of triglyceride-rich lipoproteins from human and mouse apoCIII transgenic mice
28. Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice. Apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein E
29. Alterations in lipoprotein metabolism in peroxisome proliferator-activated receptor alpha-deficient mice
30. Transcriptional regulation of human apolipoprotein genes ApoB, ApoCIII, and ApoAII by members of the steroid hormone receptor superfamily HNF-4, ARP-1, EAR-2, and EAR-3
31. Retinoids increase human apo C-III expression at the transcriptional level via the retinoid X receptor. Contribution to the hypertriglyceridemic action of retinoids
32. A multicenter comparison of the effects of simvastatin and fenofibrate therapy in severe primary hypercholesterolemia, with particular emphasis on lipoproteins defined by their apolipoprotein composition
33. Effect of gemfibrozil on the regulation of HDL subfractions in hypertriglyceridaemic patients
34. Randomized crossover study of gemfibrozil versus lovastatin in familial combined hyperlipidemia: Additive effects of combination treatment on lipid regulation
35. Multicenter comparison of micronized fenofibrate and simvastatin in patients with primary type IIA or IIb hyperlipoproteinemia
36. Effects of regular and extendedrelease gemfibrozil on plasma lipoproteins and apolipoproteins in hypercholesterolemic patients with decreased HDL cholesterol levels
37. Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice
38. CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors
39. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway
40. Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity
41. Variation in the PPARalpha gene is associated with altered function in vitro and plasma lipid concentrations in Type II diabetic subjects
42. Mutation screening of the PPARalpha gene in type 2 diabetes associated with coronary heart disease
43. Fibrate-modulated expression of fibrinogen, plasminogen activator inhibitor-1 and apolipoprotein A-I in cultured cynomolgus monkey hepatocytes: Role of the peroxisome proliferator-activated receptor-alpha
44. Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia
45. Effects of gemfibrozil and ciprofibrate on plasma levels of tissue-type plasminogen activator, plasminogen activator inhibitor-1 and fibrinogen in hyperlipidaemic patients
46. Fibrates suppress fibrinogen gene expression in rodents via activation of the peroxisome proliferator-activated receptor-alpha
47. PPARalpha agonists inhibit tissue factor expression in human monocytes and macrophages
48. The pathogenesis of atherosclerosis: A perspective for the 1990s
49. Expression of peroxisome proliferator-activated receptor alpha (PPARα) in primary cultures of human vascular endothelial cells
50. Expression of the peroxisome proliferator-activated receptor gamma (PPARγ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein
51. Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages
52. The PPARα-leukotriene B4 pathway to inflammation control
53. Inhibition of inducible nitric oxide synthase by peroxisome proliferator-activated receptor agonists: Correlation with induction of heme oxygenase 1
54. Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators
55. Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1
56. Prevention of the angiographic progression of coronary and veingraft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol
57. Associations between lipoproteins and the progression of coronary and vein-graft atherosclerosis in a controlled trial with gemfibrozil in men with low baseline levels of HDL cholesterol
58. Design features of a five-year Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT)
59. Secondary preventive potential of lipid-lowering drugs. The Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT)
60. Effect of bezafibrate treatment over five years on coronary plaques causing 20% to 50% diameter narrowing (The Bezafibrate Coronary Atherosclerosis Intervention Trial [BECAIT])
61. Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT)
62. Baseline characteristics of patients participating in the Bezafibrate Infarction Prevention (BIP) Study
63. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients
64. The Bezafibrate Infarction Prevention (BIP) study results
65. The Diabetes Atherosclerosis Intervention Study (DAIS): A study conducted in cooperation with the World Health Organization. The DAIS Project Group